Advancing Precision TIL Therapy Through Functional Biomarkers & Predictive Response Signatures
- Leveraging pre-treatment tumor biopsies and predictive biomarkers to identify patients most likely to benefit from TIL therapy across melanoma and tumors solid tumors
- Moving beyond phenotype-based markers such as PD-1 and CD39 by incorporating functional measures of autologous tumor reactivity and T-cell potency
- Translating tumor and T-cell intrinsic mechanisms of response and resistance into clinically actionable frameworks for patient selection, product optimization, and treatment decision-making